Abstract
Specific constellations of lipoprotein particle features, reflected as differences in mean lipoprotein particle diameters, are associated with risk of insulin resistance (IR) and cardiovascular disease (CVD). The associations of lipid profiles with disease risk differ by race/ethnicity, the reason for this is not clear. We aimed to examine whether there were additional genetic differences between racial/ethnic groups on lipoprotein profile. Genotypes were assessed using the Affymetrix 6.0 array in 817 related Caucasian participants of the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN). Association analysis was conducted on fasting mean particle diameters using linear models, adjusted for age, sex and study center as fixed effects, and pedigree as a random effect. Replication of associations reaching P < 1.97 × 10−05 (the level at which we achieved at least 80 % power to replicate SNP-phenotype associations) was conducted in the Caucasian population of the Multi-Ethnic Study of Atherosclerosis (MESA; N = 2,430). Variants which replicated across both Caucasian populations were subsequently tested for association in the African-American (N = 1,594), Chinese (N = 758), and Hispanic (N = 1,422) populations of MESA. Variants in the APOB gene region were significantly associated with mean VLDL diameter in GOLDN, and in the Caucasian and Hispanic populations of MESA, while variation in the hepatic lipase (LIPC) gene was associated with mean HDL diameter in both Caucasians populations only. Our findings suggest that the genetic underpinnings of mean lipoprotein diameter differ by race/ethnicity. As lipoprotein diameters are modifiable, this may lead new strategies to modify lipoprotein profiles during the reduction of IR that are sensitive to race/ethnicity.
Similar content being viewed by others
References
Aouizerat BE, Kulkarni M, Heilbron D, Drown D, Raskin S, Pullinger CR, Malloy MJ et al (2003) Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids. J Lipid Res 44(6):1167–1173
Atkinson B, Thereau T (2007) Kinship: mixed-effects Cox models, sparse matrices, and modeling data from large pedigrees. R package version, 1(1.0–17)
Austin MA, Talmud PJ, Luong LA, Haddad L, Day IN, Newman B, Edwards KL et al (1998) Candidate-gene studies of the atherogenic lipoprotein phenotype: a sib-pair linkage analysis of DZ women twins. Am J Human Genetics 62(2):406–419
Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (Oxford, England) 21(2):263–265
Beard CM, Barnard RJ, Robbins DC, Ordovas JM, Schaefer EJ (1996) Effects of diet and exercise on qualitative and quantitative measures of LDL and its susceptibility to oxidation. Arterioscler Thromb Vasc Biol 16(2):201–207
Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B (Methodol) 57(1):289–300
Bild DE (2002) Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 156(9):871–881
Chasman DI, Paré G, Mora S, Hopewell JC, Peloso G, Clarke R, Cupples LA et al. (2009) Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. (GR. Abecasis, Ed.) PLoS Genet, 5(11):e1000730
Couture P, Otvos JD, Cupples LA, Lahoz C, Wilson PWF, Schaefer EJ, Ordovas JM (2000) Association of the C-514T polymorphism in the hepatic lipase gene with variations in lipoprotein subclass profiles: the Framingham offspring study. Arterioscler Thromb Vasc Biol 20(3):815–822
Festa A, Williams K, Hanley AJ, Otvos JD, Goff DC, Wagenknecht LE, Haffner SM (2005) Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the insulin resistance atherosclerosis study. Circulation, 111:3465–3472. Department of Medicine, University of Texas Health Science Center, San Antonio, TX 78229-3900, USA
Frazier-Wood AC, Aslibekyan S, Borecki IB, Hopkins PN, Lai CQ, Ordovas JM, Straka RJ et al (2012) Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate. Pharmacogenet Genomics 22(10):750–757
Freeman D (2003) A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland coronary prevention study. Eur Heart J 24(20):1833–1842
Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K et al (2003) Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52:453–462
Goff DC Jr, D’Agostino RB Jr, Haffner SM, Otvos JD (2005) Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the insulin resistance atherosclerosis study. Metabolism 54:264–270
Goodarzi MO, Guo X, Taylor KD, Quiñones MJ, Samayoa C, Yang H, Saad MF et al (2003) Determination and use of haplotypes: ethnic comparison and association of the lipoprotein lipase gene and coronary artery disease in Mexican-Americans. Genet Med 5(4):322–327
Gray RS, Robbins DC, Wang W, Yeh JL, Fabsitz RR, Cowan LD, Welty TK et al (1997) Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians. The Strong Heart Study. Arterioscler Thromb Vasc Biol 17:2713–2720
Jeyarajah EJ, Cromwell WC, Otvos JD (2006) Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 26(4):847–870
Kabagambe EK, Ordovas JM, Tsai MY, Borecki IB, Hopkins PN, Glasser SP, Arnett DK (2009) Smoking, inflammatory patterns and postprandial hypertriglyceridemia. Atherosclerosis 203:633–639
Korn JM, Kuruvilla FG, McCarroll SA, Wysoker A, Nemesh J, Cawley S, Hubbell E et al (2008) Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. Nat Genet 40(10):1253–1260
Kral BG, Becker LC, Yook RM, Blumenthal RS, Kwiterovich PO, Otvos JD, Becker DM (2001) Racial differences in low-density lipoprotein particle size in families at high risk for premature coronary heart disease. Ethn Dis 11(2):325–337
Kullo IJ, Jan MF, Bailey KR, Mosley TH, Turner ST (2007) Ethnic differences in low-density lipoprotein particle size in hypertensive adults. J Clin Lipidol 1(3):218–224
Lemieux I, Laperrière L, Dzavik V, Tremblay G, Bourgeois J, Després J-P (2002) A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. Atherosclerosis 162(2):363–371
Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M (2010) Robust relationship inference in genome-wide association studies. Bioinformatics (Oxford, England) 26(22):2867–2873
Melenovsky V, Malik J, Wichterle D, Simek J, Pisarikova A, Skrha J, Poledne R et al (2002) Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J 144(4):E11–E18
Nature Publishing Group (2012) Asking for more. Nature Genet 44(7):733
Nettleton JA, Steffen LM, Ballantyne CM, Boerwinkle E, Folsom AR (2007) Associations between HDL-cholesterol and polymorphisms in hepatic lipase and lipoprotein lipase genes are modified by dietary fat intake in African American and White adults. Atherosclerosis 194(2):e131–e140
Nishina PM, Johnson JP, Naggert JK, Krauss RM (1992) Linkage of atherogenic lipoprotein phenotype to the low density lipoprotein receptor locus on the short arm of chromosome 19. Proc Natl Acad Sci USA 89:0027–8424
O’Meara JG, Kardia SLR, Armon JJ, Brown CA, Boerwinkle E, Turner ST (2004) Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med 164(12):1313–1318
Okumura K, Matsui H, Ogawa Y, Takahashi R, Matsubara K, Imai H, Imamura A et al (2003) The polymorphism of the beta3-adrenergic receptor gene is associated with reduced low-density lipoprotein particle size. Metabolism 52:356–361
Osgood D (2003) Genetic variation at the scavenger receptor class B type I gene locus determines plasma lipoprotein concentrations and particle size and interacts with type 2 diabetes: the Framingham study. J Clin Endocrinol Metab 88:2869–2879
Rotter JI, Bu X, Cantor RM, Warden CH, Brown J, Gray RJ, Blanche PJ et al (1996) Multilocus genetic determinants of LDL particle size in coronary artery disease families. Am J Hum Genet 58:585–594
Ruel IL, Gaudet D, Perron P, Bergeron J, Julien P, Lamarche B (2002) Characterization of LDL particle size among carriers of a defective or a null mutation in the lipoprotein lipase gene: the Quebec LIPD Study. Arterioscler Thromb Vasc Biol 22:1181–1186
Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100(16):9440–9445
Talmud PJ, Edwards KL, Turner CM, Newman B, Jutta M, Humphries SE, Austin MA et al (2000) Linkage of the cholesteryl ester transfer protein (CETP) gene to LDL particle size. Use of a novel tetranucleotide repeat within the CETP promoter. Circulation 101:2461–2466
Talmud PJ, Martin S, Taskinen M-R, Frick MH, Nieminen MS, Kesäniemi YA, Pasternack A et al (2004) APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study. J Lipid Res 45(4):750–756
Wang J, Qiang H, Chen D, Zhang C, Zhuang Y (2002) CETP gene mutation (D442G) increases low-density lipoprotein particle size in patients with coronary heart disease. Clin Chim Acta 322:85–90
Wood RJ, Volek JS, Liu Y, Shachter NS, Contois JH, Fernandez ML (2006) Carbohydrate restriction alters lipoprotein metabolism by modifying VLDL, LDL, and HDL subfraction distribution and size in overweight men. J Nutr 136(2):384–389
Wung S-F, Aouizerat BE (2003) Gender and ethnic differences in a case-control study of dyslipidemia: using the apolipoprotein A-V gene as an exemplar in cardiovascular genetics. Res Theory Nurs Pract 17(4):281–299
Acknowledgments
We are grateful to the staff of the GOLDN study for the assistance in data collection and management. The authors thank the participants of the MESA study, the Coordinating Center, MESA investigators, and study staff for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. GOLDN is funded by National Heart, Lung, and Blood Institute [grant number U01HL072524-04]. MESA and the MESA SHARe project are conducted and supported by contracts N01-HC-95159 through N01-HC-95169 and RR-024156 from the National Heart, Lung, and Blood Institute. Funding for MESA SHARe genotyping was provided by National Heart, Lung, and Blood Institute [Contract N02‐HL‐6‐4278]. MESA Family is conducted and supported in collaboration with MESA investigators; support is provided by National Heart, Lung, and Blood Institute grants and contracts [grant numbers R01HL071051, R01HL071205, R01HL071250, R01HL071251, R01HL071252, R01HL071258, R01HL071259].
Conflict of interest
All authors declare that they have no conflicts of interests.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Frazier-Wood, A.C., Manichaikul, A., Aslibekyan, S. et al. Genetic variants associated with VLDL, LDL and HDL particle size differ with race/ethnicity. Hum Genet 132, 405–413 (2013). https://doi.org/10.1007/s00439-012-1256-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00439-012-1256-1